Generics applications under review by EMA

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Generics applications under review by EMA – 2013 Q4

Generics/General | Posted 10/01/2014 0 Post your comment

Last update: 20 January 2014

Generic medicines in Europe can be approved either centrally via the European Medicines Agency (EMA) or nationally via the local regulatory body [1]. Approval by EMA takes place by using a centralized procedure. This leads to approval of the product in all 28 European Union (EU) Member States and in Iceland, Liechtenstein and Norway. At a country level, if approval in a single EU Member State only is required, this can take place using the national procedure. However, as soon as a company seeks approval in two or more Member States, a decentralized procedure or mutual recognition procedure must be used [2].

According to EMA’s list of applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use released on 5 December 2013, the agency is currently reviewing six applications for marketing approval in the EU for generics. The applications include one for dementia treatment rivastigmine, for which there are already generics approved by EMA, see Table 1.

First-time European generics under review by EMA include one for a generic version of AstraZeneca’s chronic obstructive pulmonary disease treatment Symbicort (budesonide/formoterol), one for a generic version of Otsuka Pharmaceutical’s Busulfex (busulfan), one for Roche’s flu treatment Tamiflu (oseltamivir), one for a generic version of Advagraf/Modigraf (tacrolimus), made by Astellas; and one for a generic version of bone cancer treatment Aclasta/Zometa (zoledronic acid), made by Novartis.

Table 1: Generics under review by EMA*

Common name	Therapeutic area	Number of applications	Originator product	Originator company
Budesonide/ formoterol	Obstructive airway diseases	1	Symbicort	AstraZeneca
Busulfan	Haematopoietic stem cell transplantation	1	Busulfex/Busilvex	Otsuka Pharmaceutical
Oseltamivir	Antiviral (flu treatment)	1	Tamiflu	Genentech (Roche)
Rivastigmine	Psychoanaleptic (Alzheimer’s & Parkinson’s disease)	1	Exelon	Novartis
Tacrolimus	Immunosuppressant (organ rejection)	1	Advagraf/Modigraf	Astellas
Zoledronic acid	Bone disease	1	Aclasta/Zometa	Novartis
Total		6
*Data collected on 7 January 2014. Source: EMA

On 4 December 2013, a Memantine generic, Memantine Accord, produced by Accord Healthcare received marketing authorization for the EU. The generic drug is indicated for the treatment of patients with moderate to severe Alzheimer’s disease. There are now 11 different memantine drugs including the originator Axura approved by EMA for the EU.

Since the last report by GaBI Online for 2013 Q3, EMA has removed generic levetiracetam and a generic zoledronic acid from its list. However, no marketing authorizations have appeared on the agency’s website, leading GaBI Online to believe that these applications have been withdrawn.

Related articles

Generics applications under review by EMA – 2013 Q3

Generics applications under review by EMA – 2013 Q2

Alzheimer generic launched in the US

References

1. GaBI Online - Generics and Biosimilars Initiative. EU guidelines for generics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jan 10]. Available from: www.gabionline.net/Guidelines/EU-guidelines-for-generics

2. GaBI Online - Generics and Biosimilars Initiative. Registration procedures for generic drugs in the EU [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jan 10]. Available from: www.gabionline.net/Reports/Registration-procedures-for-generic-drugs-in-the-EU

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: EMA